Harbour BioMed nets $75M in Series B+ as first global trial gets underway
Nearly two years after drawing an $85 million Series B, Shanghai-based Harbour BioMed has announced a new large funding round.
In what they’re billing as a “Series B+,” Harbour has raised $75 million to help push the biotech’s antibodies further in the clinic and develop more in-house candidates. The round included new investors such as SK Holdings, Greater Bay Area Fund and Efung Capital, who joined returning funds Legend Capital, AdvanTech and GIC, also known as Singapore’s sovereign wealth fund.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.